Clinical Trials Browser

Mycosis Fungoides × pembrolizumab × Dermatologic × Clear all

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03598998 2025-06-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Phase 1/2 Active not recruiting

13 enrolled 12 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT03385226 2024-12-09

PORT

Phase 2 Active not recruiting

46 enrolled

DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT03617224 2020-04-22

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

Phase 1 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Clinical Trials

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

PORT

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome